NasdaqGM:AUPHBiotechs
How Aurinia’s Tang-Led C-Suite Overhaul Will Impact Aurinia Pharmaceuticals (AUPH) Investors
In March 2026, Aurinia Pharmaceuticals underwent a sweeping leadership overhaul, with Board Chair Kevin Tang becoming CEO and principal executive officer, joined by new CFO Michael Hearne, COO Ryan Cole, and Chief Scientific Officer Thomas Wei as several prior C-suite leaders departed.
This reshuffle consolidates operational control around Tang Capital–linked executives, signaling a potential shift in how Aurinia balances capital allocation, operations, and pipeline priorities.
Next, we’ll...